Inhibition of the oxidative and nonoxidative pentose phosphate pathways by somatostatin: A possible mechanism of antitumor action

Medical Hypotheses

Volumn 50, Issue 6, 1998, Pages 501-506

  Boros, L G ^a,d   Brandes, J L ^a   Yusuf, F I ^a   Cascante, M ^b   Williams, R D ^c   Schirmer, W J ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF BARCELONA   (Spain)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^d Wiseman Hall ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; OXYTHIAMINE; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; TRANSKETOLASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; DRUG EFFECT; GLUCOSE INTOLERANCE; GLUCOSE UTILIZATION; GLYCOLYSIS; HUMAN; NONHUMAN; OXIDATION; PANCREAS ADENOCARCINOMA; PENTOSE PHOSPHATE CYCLE; PRIORITY JOURNAL;

EID: 0031750794     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(98)90271-7     Document Type: Article

References (36)

1. Assan R. Somatostatin, a new hormone? [French]. Diabete Metabo 1976; 2(3): 135-146.
2. Theologides A. Anorexia-producing intermediary metabolites. Am J Clin Nutr 1976; 29(5): 552-558.
3. Del Pozo E. Clinical applications of Somatostatin [review]. Hormone Res 1988; 29(2-3): 89-91
4. Srkalovic G, Cai R Z, Schally A V. Evaluation of receptors for Somatostatin in various tumors using different analogs. J Clin Endocrinol Metabol 1990; 70(3): 661-669.
5. Schally A V, Srkalovic G, Szende B et al. Antitumor effects of analogs of LH-RH and Somatostatin: experimental and clinical studies [review]. J Steroid Biochem Mol Biol 1990; 37(6): 1061-1067.
6. Liebow C, Lee M T, Schally A. Antitumor effects of somatostatin mediated by the stimulation of tyrosine phosphatase. Metabol Clin Exp 1990; 39(9, suppl. 2): 163-166.
7. Van Tol E A, Verspaget H W, Lamers C B. Neuropeptide regulation of cell-mediated cytotoxicity against human tumor cells. Neuropeptides 1990; 16(1): 25-32.
8. Reubi J C, Krenning E, Lamberts S W, Kvols L. In vitro detection of Somatostatin receptors in human tumors [review]. Digestion 1993; 54(Suppl. 1): 76-83.
9. Warburg O. The Metabolism of Tumors. London: Constable, 1930.
10. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-314.
11. Raylman R R, Fisher S J, Brown R S, Ethier S P, Wahl R L. Fluorine-18-fluorodeoxy-glucose guided breast cancer surgery with a positron-sensitive probe: validation in preclinical studies. J Nucl Med 1995; 36(10): 1869-1874.
12. Torizuka T, Tamaki N, Inokuma T et al. In vivo assessment of glucose metabolism in hepato-cellular carcinoma with FDG-PET. J Nucl Med 1995; 36(10): 1811-1817.
13. Strauss L G, Conti P S. The application of PET in clinical oncology. J Nucl Med 1991; 32: 623-648.
14. Bares R, Klever P, Hauptmann S et al. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology 1994; 192(1): 79-86.
15. Francavilla T L, Miletich R S, DeMichele D et al. Positron emission tomography of pituitary macroadenomas: hormone production and effects of therapies. Neurosurgery 1991; 28(6): 826-833.
16. Moler C, Benito M, Lorenzo M. Glucose-6-phosphate dehydrogenase gene expression in fetal hepatocyte primary cultures under nonproliferative and proliferative conditions. Exp Cell Res 1994; 210: 26-32.
17. Jonas S K, Benedetto C, Flatman A et al. Increased activity of 6-phosphogluconate dehydrogenase and glucose-6-phosphate dehydrogenase in purified cell suspension and single cells from the uterine cervix in cervical intraepithelial neoplasia. Br J Cancer 1992; 66: 185-191.
18. Geertrudia N J, Ilse M C, Klazina S B, Dingemans K P, Kornelis J F. Experimentally induced colon cancer metastases in rat liver increase the proliferation rate and capacity for purine catabolism in liver cells. Histochemistry 1993; 100: 41-51.
19. Cocco P, Dessi S, Avataneo G, Picchiri G, Heinemann E. Glucose-6-phosphate dehydrogenase deficiency and cancer in a Sardinian male population: a case control study. Carcinogenesis 1989; 10(5): 813-816.
20. Lehninger A L. Biochemistry, Vol. 2. New York: Worth, 1975.
21. Eilertson C D, Sheridan M A. Differential effects of somatostatin-14 and somatostatin-25 on carbohydrate and lipid metabolism in rainbow trout Oncorhynchus mykiss. Gen Compar Endocrinol 1993; 92(1): 62-70.
22. Harmon J S, Eilertson C D, Sheridan M A, Plisetskaya E M. Insulin suppression is associated with hypersomatostatinemia and hyperglucagonemia in glucose-injected rainbow trout. Am J Physiol 1991; 261(3, Pt 2): R609-613.
23. Basu T K, Dickerson J W. The thiamin status of early cancer patients with particular reference to those with breast and bronchial carcinomas. Oncology 1976; 33(5-6): 250-252.
24. Zimatkina T I, Zimatkin S M, Oparin D A, Velichko M G, Ostrovskii I M. Comparative evaluation of the action of oxythiamine and its derivatives on animals with Erhlich's ascitic cancer [Russian]. Eksperimentalnaia Onkologiia 1986; 8(2): 68-70.
25. Trebukhina R V, Kraskovskii G V, Mel'nov S B, Motylevich Zh V, Mel'nova N I. The effect of oxythiamine on tumor growth and certain biochemical and genetic characteristics of normal and tumor cells [Russian]. Vopr Med Khim 1992; 38(5): 20-22
26. Rempel A, Mathupala S P, Perdersen P L. Glucose catabolism in cancer cells: regulation of the Type II hexokinase promoter by glucose and cyclic AMP. FEBS Lett 1996; 385(3): 233-237.
27. Eigenbrodt E, Reinacher M, Schefers-Borchel U, Schefers H, Friis R. Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells. Crit Rev Oncogenesis 1992; 3(1-2): 91-115.
28. Lee W N P, Boros L G, Brandes J L et al. Non-oxidative pathway of ribose synthesis in cultured pancreatic adenocarcinoma cells. American Federation for Clinical Research, February 1997, Carmel, California.
29. Melvin W S, Boros L G, Muscarella P. Dehydroepiandrosterone sulfate inhibits pancreatic carcinoma cell proliferation in vitro and in vivo. Surgery (in press).
30. Boros L G. Characterization of ribose synthetic pathways in tumors. OSURF Proposal Number 54334-55-00, Grant and Contract Management, The Ohio State University Research Foundation, 1997: 30-32.
31. Fisher W E, Boros L G, O'Dorisio T M, O'Dorisio S M, Schirmer W J. Insulin promotes pancreatic cancer: evidence for endocrine influence on exocrine pancreatic tumors. J Surg Res 1996; 63: 310-313.
32. Fisher W E, Boros L G, O'Dorisio T M, O'Dorisio M S, Schirmer W J. GI hormonal changes in diabetes influence pancreatic cancer growth. J Surg Res 1995; 58(6): 754-758.
33. Summers M L, Wallis J G, Campbell E L, Meeks J C. Genetic evidence of a major role for glucose-6-phosphate dehydrogenase in nitrogen fixation and dark growth of the cyanobacterium Nostoc sp. strain ATCC 29133. J Bacteriol 1995; 177(21): 6184-6194.
34. Paoli G C, Morgan N S, Tabita F R, Shively J M. Expression of the cbbLcbbS and cbbM genes and distinct organization of the ebb Calvin cycle structural genes of Rhodobacter capsulatus. Arch Microbiol 1995; 164(6): 396-405.
35. Haines G K, Cajulis R, Hayden R, Duda R, Talamonti M, Radosevich J A. Expression of the double-stranded RNA-dependent protein kinase (p68) in human breast tissues. Tumour Biol 1996; 17: 5-12.
36. Schimmer B P, Tsao J, Czerwinski W. Amplification of the transketolase gene in desensitization-resistant mutant Y1 mouse adrenocortical tumor cells. J Biol Chem 1996; 271: 4993-4998.